<?xml version='1.0' encoding='utf-8'?>
<document id="28639119"><sentence text="A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects." /><sentence text="In vitro data showed that selexipag and its active metabolite (ACT-333679) have an inductive effect on CYP3A4, CYP2B6, and CYP2C9 at concentrations approximately 100-fold higher than the maximum plasma concentration (C max) measured under steady-state conditions" /><sentence text=" In order to confirm in vivo the lack of induction at the enterocyte level, we assessed the effect of selexipag on midazolam, a substrate of hepatic and intestinal CYP3A4" /><sentence text="" /><sentence text="This study was conducted according to an open-label, randomized, two-way crossover design" /><sentence text=" A total of 20 subjects received a single oral dose of 7" /><sentence text="5 mg midazolam alone (treatment A) or on top of steady-state selexipag (treatment B)" /><sentence text=" Selexipag was administered twice daily using an up-titration scheme consisting of three steps: 400, 600, 1000, and 1600 μg with increments every fourth day" /><sentence text=" A 24-h pharmacokinetic profile was performed following midazolam administration, and bioequivalence criteria were investigated on an exploratory basis"><entity charOffset="56-65" id="DDI-PubMed.28639119.s9.e0" text="midazolam" /></sentence><sentence text="" /><sentence text="The C max of midazolam and 1-hydroxymidazolam was decreased by approximately 20 and 14%, respectively, following treatment B compared to A"><entity charOffset="13-22" id="DDI-PubMed.28639119.s11.e0" text="midazolam" /><entity charOffset="27-45" id="DDI-PubMed.28639119.s11.e1" text="1-hydroxymidazolam" /><pair ddi="false" e1="DDI-PubMed.28639119.s11.e0" e2="DDI-PubMed.28639119.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28639119.s11.e0" e2="DDI-PubMed.28639119.s11.e1" /></sentence><sentence text=" The time to reach C max for midazolam and 1-hydroxymidazolam was similar between treatments"><entity charOffset="43-61" id="DDI-PubMed.28639119.s12.e0" text="1-hydroxymidazolam" /></sentence><sentence text=" The terminal half-life was reduced in treatment B compared to A for both midazolam (16%) and 1-hydroxymidazolam (20%)"><entity charOffset="74-83" id="DDI-PubMed.28639119.s13.e0" text="midazolam" /><entity charOffset="94-112" id="DDI-PubMed.28639119.s13.e1" text="1-hydroxymidazolam" /><pair ddi="false" e1="DDI-PubMed.28639119.s13.e0" e2="DDI-PubMed.28639119.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28639119.s13.e0" e2="DDI-PubMed.28639119.s13.e1" /></sentence><sentence text=" Exposure (area under the curve) to midazolam and 1-hydroxymidazolam was similar between treatments, and the 90% confidence intervals of geometric mean ratios were within the bioequivalence interval"><entity charOffset="50-68" id="DDI-PubMed.28639119.s14.e0" text="1-hydroxymidazolam" /></sentence><sentence text=" Treatment with midazolam, selexipag, and the combination was safe and well tolerated"><entity charOffset="16-25" id="DDI-PubMed.28639119.s15.e0" text="midazolam" /></sentence><sentence text="" /><sentence text="Exposure to midazolam and 1-hydroxymidazolam was not affected by treatment with selexipag"><entity charOffset="12-21" id="DDI-PubMed.28639119.s17.e0" text="midazolam" /><entity charOffset="26-44" id="DDI-PubMed.28639119.s17.e1" text="1-hydroxymidazolam" /><pair ddi="false" e1="DDI-PubMed.28639119.s17.e0" e2="DDI-PubMed.28639119.s17.e0" /><pair ddi="false" e1="DDI-PubMed.28639119.s17.e0" e2="DDI-PubMed.28639119.s17.e1" /></sentence><sentence text="" /></document>